Accessibility Menu
Revvity logo

Revvity(NYSE) RVTY

Market Cap$12.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+7,188%
5 Year-40%
1 Year+26%
1 Month-2%
$111.07
-3.60%
-4.15Today
After hours$111.32+$0.25 (+0.23%)
Revvity last closing stock price
MetricPriceDate
Last closeUSD 111.392026-08-04
Revvity stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.11%USD 111.512026-07-28
1 month-2.02%USD 113.692026-07-02
3 month+12.48%USD 99.032026-05-06
Year to date+15.36%USD 96.562025-12-31
1 year+26.47%USD 88.082025-08-04
3 year-8.88%USD 122.252023-08-04
5 year-39.73%USD 184.832021-08-05
Since inception+7,187.86%USD 1.581968-01-02

Revvity Financials at a Glance

Market Cap

$12.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.91B

Net Income (TTM)

$237.55M

EPS (TTM)

$2.11

P/E Ratio

54.61

Dividend

$0.28

Beta (Volatility)

1.05 (Average)

Price

$111.07

Volume

2,587,309

Open

$114.50

Previous Close

$111.39

Daily Range

$107.73 - $117.37

52-Week Range

$81.22 - $118.30

Estimated Earnings Date

Aug 4, 2026

RVTY News

Foolcom-Featured.png

Revvity Q2 Revenue Up 4 Percent

Motley Fool Markets TeamJul 28, 2025
woman lab science research STEM

Why Revvity Stock Plunged Today

Steve SymingtonOct 30, 2023
GettyImages-1193695668

Why Shares of PerkinElmer Dropped 14.4% in January

James HalleyFeb 7, 2022
IRS building sign and stoplight Internal Revenue Service headquarters

3 Strong Stocks for Your Income Tax Return

James HalleyMay 25, 2021
COVID test

How PerkinElmer Beat Expectations in Q4

Keith SpeightsFeb 3, 2021
research scientists drugs pharma biotech (1)

Why Is Nobody Talking About PerkinElmer Stock?

James HalleyJan 5, 2021
GettyImages-1212780825

The FDA Just Ranked Coronavirus Tests by Sensitivity. Here's What That Means

Alex CarchidiOct 3, 2020
Coronavirus positive test

FDA Evaluates 5 More COVID-19 Antibody Tests

Brian Orelli, PhDJun 5, 2020
Page 1

RVTY: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Revvity

Revvity helps scientists and doctors find better ways to treat and prevent diseases. It makes tools that test for health issues in babies and adults across more than 160 countries. These products help researchers study new medicines and run medical labs more efficiently.

What Revvity Offers the World

  • Life Sciences: Instruments and reagents used by drug companies and academic labs to research gene function and discover new medicines.
  • Diagnostics: Testing platforms and software for early detection of genetic disorders and infectious diseases in hospitals and clinics.
  • Immunodiagnostics: Specialized technology used to detect immune system responses to infections like tuberculosis.
  • Reproductive Health: Screening tools and software designed to check the health of expectant mothers and their newborn babies.
  • Informatics: Software and cloud-based systems that help researchers organize and analyze large amounts of scientific data.

Recent Steps Forward

  • Changed the corporate name from PerkinElmer to Revvity in April 2023.
  • Expanded the Pin-point base editing platform through a collaboration with Profluent to improve gene therapy tools.
  • Introduced the AssayMate workstation in 2025 to automate liquid handling in laboratory research.
  • Acquired new software capabilities such as Katalyst D2D and Luminata to help pharmaceutical companies manage experimental data.

What Makes the Company Stand Out

Revvity maintains a global presence with roughly 80% of its 11,000 employees based outside the United States. The company holds numerous patents and uses its own specialized sales force to reach customers in 160 different countries.

The Recent Financial Scorecard

  • Revenue reached $772.1 million in Q4 2025, up 5.9% from Q4 2024.
  • Net income grew to $98.4 million in Q4 2025, a 3.5% increase year-over-year.
  • Free cash flow was $163.1 million in Q4 2025, up 8.9% from the previous year.
  • Operating income fell to $111.7 million in Q4 2025, down 15.5% from Q4 2024.
  • The company maintained $9 billion in net intangible assets as of December 28, 2025.

The Bottom Line

Revvity has transitioned from a general industrial technology firm into a specialized health science provider. This evolution focuses on high-growth areas like gene editing and early medical diagnosis to meet global healthcare needs.

AI Generated • Apr 21, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

11,000

CEO

Prahlad Ramadhar Singh, PhD, MBA

Website

www.revvity.com

Headquarters

Waltham, MA 02451, US

RVTY Financials

Key Financial Metrics (TTM)

Gross Margin

52.11%

Operating Margin

12.32%

Net Income Margin

8.16%

Return on Equity

3.27%

Return on Capital

3.31%

Return on Assets

1.97%

Earnings Yield

1.83%

Dividend Yield

0.24%

Payout Ratio

13.36%

Stock Overview

Market Cap

$12.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

111.56M

Volume

2.59M

Avg. Volume

1.54M

Financials (TTM)

Gross Profit

$1.52B

Operating Income

$358.85M

EBITDA

$767.00M

Operating Cash Flow

$632.49M

Capital Expenditure

-$69.52M

Free Cash Flow

$562.97M

Cash & ST Invst.

$1.02B

Total Debt

$3.34B

Revvity Performance Analysis

Revvity annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,311,822,000-13.5%
20232023-12-31USD 2,750,571,000-16.9%
20242024-12-31USD 2,755,026,0000.2%
20252025-12-31USD 2,856,051,0003.7%
Revvity sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-28-3.0%
Q42025-12-2810.5%
Q12026-04-05-7.9%
Q22026-07-052.6%
Revvity annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 4.50-44.3%
20232023-12-31USD -0.95N/A
20242024-12-31USD 2.41N/A
20252025-12-31USD 2.08-13.8%
Revvity sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-28-14.9%
Q42025-12-28117.5%
Q12026-04-05-58.6%
Q22026-07-0530.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$729.69M

+1.3%

Gross Profit

$416.87M

+6.2%

Gross Margin

57.13%

N/A

Market Cap

$12.85BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.17M

N/A

Employees

11,000

N/A

Net Income

$51.82M

-6.2%

EBITDA

$188.56M

-3.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.02B

+3.1%

Total Debt

$3.34B

-1.0%

Accounts Receivable

$709.18M

+7.3%

Inventory

$378.50M

-2.6%

Long Term Debt

$2.77B

-17.9%

Short Term Debt

$572.16M

+248663.5%

Return on Assets

1.97%

N/A

Return on Invested Capital

3.33%

N/A

Free Cash Flow

$184.50M

+59.8%

Operating Cash Flow

$195.57M

+45.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALGNAlign Technology, Inc.
$173.27+0.22%
ICLRICON Public Limited Company
$156.85-0.98%
CRLCharles River Laboratories International, Inc.
$234.12+1.41%
SOLVSolventum Corporation
$87.94-0.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About RVTY

What is the current price of Revvity?

Revvity is trading at $111.39 per share.

What is the 52-week range for Revvity?

Over the past 52 weeks, Revvity has traded between $81.22 and $118.30.

How much debt does Revvity have?

As of the most recent reporting period, Revvity reported total debt of $3.35B.

How much cash does Revvity have on hand?

Revvity reported $860.75M in cash and cash equivalents in its most recent financial results.

What is Revvity’s dividend yield?

Revvity currently has a dividend yield of 0.24%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services